U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Reblozyl® (luspatercept-aamt) for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who…

Read MoreU.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

LIB Therapeutics Announces Positive Results from the Phase 3 Long-term Efficacy and Safety of Lerodalcibep in Heterozygous Familial Hypercholesterolemia (LIBerate-HeFH) Trial

LIB Therapeutics Inc., a clinical-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor medicines for patients at very high and high risk of cardiovascular disease (“CVD”) requiring additional reductions in LDL- cholesterol (“LDL-C” or “LDL”), in patients on maximally tolerated…

Read MoreLIB Therapeutics Announces Positive Results from the Phase 3 Long-term Efficacy and Safety of Lerodalcibep in Heterozygous Familial Hypercholesterolemia (LIBerate-HeFH) Trial
RestorixHealth

Octave® Bioscience, Inc.’s Solution for Transforming the Care Paradigm in MS has been Selected as a Finalist in Fast Company’s 2023 Innovation by Design Awards

Octave® Bioscience, Inc. was honored in Fast Company’s Innovation by Design Awards for 2023 in the Health category. The Innovation by Design Awards, which can be found in the September 2023 issue of Fast Company, honor the designers and businesses solving the most crucial…

Read MoreOctave® Bioscience, Inc.’s Solution for Transforming the Care Paradigm in MS has been Selected as a Finalist in Fast Company’s 2023 Innovation by Design Awards

Global Vital Signs Monitoring Devices Market Outlook & Forecast Report 2023: A $33.35+ Billion Industry by 2028 – Patient-Centric Digital Systems and Wearable Devices Drive Growth – ResearchAndMarkets.com

The global vital signs monitoring devices market is expected to reach a value of $33.36 billion by 2028 from $20.6 billion in 2022, growing at a CAGR of 8.36% from 2022 to 2028 The North American region dominated the vital…

Read MoreGlobal Vital Signs Monitoring Devices Market Outlook & Forecast Report 2023: A $33.35+ Billion Industry by 2028 – Patient-Centric Digital Systems and Wearable Devices Drive Growth – ResearchAndMarkets.com

inSpring and MGH Institute of Health Professions Team Up to Meet Critical Demand for Nurses

inSpring, a leading health care and technology talent mobility company specializing in connecting diverse, highly-skilled international job candidates in the United States with employment opportunities in nursing and technology, announced today a groundbreaking partnership with Mass General Brigham’s esteemed graduate school, MGH Institute…

Read MoreinSpring and MGH Institute of Health Professions Team Up to Meet Critical Demand for Nurses

The FNIH Awards 2023 Trailblazer Prize for Clinician-Scientists to Vinod Balachandran, M.D., from Memorial Sloan Kettering Cancer Center for Pancreatic Cancer Research

The Foundation for the National Institutes of Health (FNIH) has awarded its sixth annual Trailblazer Prize for Clinician-Scientists to Vinod Balachandran, M.D., at Memorial Sloan Kettering Cancer Center (MSK), for his groundbreaking research on immunotherapies for pancreatic cancer. The FNIH’s Trailblazer…

Read MoreThe FNIH Awards 2023 Trailblazer Prize for Clinician-Scientists to Vinod Balachandran, M.D., from Memorial Sloan Kettering Cancer Center for Pancreatic Cancer Research

Global Open Wound Care Selects eClinicalWorks EHR to Enhance Operations and Patient Care

eClinicalWorks®, the largest ambulatory cloud EHR, today announced that Global Open Wound Care—a mobile wound care clinic specializing in advanced wound treatments and point-of-care treatment decision-making—has selected eClinicalWorks EHR to enhance patient care, mobility, and practice efficiency. Global Open Wound Care…

Read MoreGlobal Open Wound Care Selects eClinicalWorks EHR to Enhance Operations and Patient Care

Novartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote

Novartis today issued the invitation to an Extraordinary General Meeting (EGM) of Novartis shareholders, scheduled to take place on September 15, 2023, in relation to the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of Novartis. At the…

Read MoreNovartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults

AbbVie (NYSE: ABBV) today announced that the European Commission has approved AQUIPTA® (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval makes AQUIPTA the first and only once-daily oral calcitonin gene-related…

Read MoreAbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults